In Japan, sales of Eisai and Biogen's Alzheimer's drug begin to accelerate
Biogen and Eisai’s Alzheimer’s drug Leqembi is off to a slow start in the US. But it’s big in Japan. On Friday, Eisai revealed in an investor presentation that Japanese revenue accounted for 1.5...
View ArticleExclusive: Devoted Health raises $112M, plots insurance markets expansion
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Devoted Health just nabbed another $112 million in venture funding to fuel its push into seven new...
View ArticleClik here to view.
Iron chelator therapy unexpectedly worsened Alzheimer’s disease in clinical...
PHILADELPHIA — Among the many mysteries of Alzheimer’s disease is the role that iron plays. The metal is vital for transporting oxygen in the blood and producing energy from mitochondria, but some...
View ArticleMassachusetts' plan for $1B in life science investment stalls in state...
Massachusetts Gov. Maura Healey’s proposal to invest another $1 billion in life sciences over the next 10 years has been imperiled after failing to make it through the state’s legislative body before...
View ArticleDoses of Lilly's blockbuster GLP-1 in shortage have been pulled from FDA...
Doses of Eli Lilly’s blockbuster weight loss and diabetes drugs that were listed as in short supply no longer are, according to the FDA’s database that tracks drugs in limited supply. The agency’s...
View ArticleAdvisory committee votes in favor of Zevra Therapeutics' rare genetic disease...
A panel of outside advisors to the FDA voted 11-5 in favor of Zevra Therapeutics’ drug for a rare genetic condition called Niemann-Pick disease type C, saying that it is effective based on current...
View ArticleEisai’s new Leqembi data; Jim Wilson’s next move; Roivant dealmaker’s payday;...
Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add...
View ArticleMBX Biosciences rakes in $63.5M for peptide therapies
MBX Biosciences raised $63.5 million in a Series C funding round, two years after closing a $115 million Series B. The biotech, which is focusing on peptide therapies for endocrine and metabolic...
View ArticleLayoffs at Sumitomo; Galderma and L’Oréal strike a deal
Plus, news about Eiger BioPharmaceuticals: Sumitomo cuts workers: The Japanese pharma is laying off 53 people in Marlborough, MA, according to an August 1 WARN notice. The layoffs will happen at the...
View ArticleClik here to view.
What the meltdown in the stock market means for biotech and pharma
On Monday, global market indices crashed after a week of soft corporate earnings, a macroeconomic warning, and concerns that the Federal Reserve had waited too long to cut interest rates. Biotech and...
View ArticleThird Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific...
Another CD20/CD3 bispecific is entering the fold, except this time for autoimmune diseases. Prolific biotech creator Third Rock Ventures and Arie Belldegrun’s Two River have joined forces to create a...
View ArticleQ&A: Genentech’s new CEO says AI is not coming for company scientists and the...
Genentech and Roche are pretty much the only two companies that Ashley Magargee knows. The biopharma veteran has spent two decades at both (including before their 2009 merger) and took over as...
View ArticleBristol Myers to cut more jobs at headquarters as part of announced restructure
Roughly two months after Bristol Myers Squibb disclosed hundreds of job cuts at its New Jersey corporate headquarters, it’s further shrinking the headcount there. Another 117 layoffs are coming to the...
View ArticleMallinckrodt sells photopheresis platform Therakos for $925M
Less than a year after emerging from its second bankruptcy, Mallinckrodt is selling its photopheresis platform Therakos to help pay off debt. Luxembourg-based CVC Capital Partners has agreed to pay...
View ArticleNuvation pauses BET inhibitor plans after checking out interim Phase 1 data
Nuvation Bio won’t take its cancer drug NUV-868 into a Phase 2 trial for now, following a look at interim safety and efficacy data from a Phase 1 trial. The disclosure came in the biotech’s...
View ArticleEliot Forster’s pain biotech unveils Phase 2 data in degenerative joint disease
UK biotech Levicept said its first-in-class biologic can help ease pain and stiffness in patients with moderate to severe osteoarthritis, according to mid-stage data released Tuesday. The Phase 2...
View ArticleClik here to view.
BioMarin scales back launch for hemophilia gene therapy, pitches path to...
BioMarin Pharmaceutical is reeling in its gene therapy ambitions. On Monday, the company announced that it’s lowering spending plans for its hemophilia gene therapy, Roctavian, and stopping development...
View ArticleExclusive: Biotech investor Sofinnova hires former Biogen medical chief
Maha Radhakrishnan, who left her post as chief medical officer at Biogen earlier this year, is now an executive partner at Sofinnova Investments, the firm exclusively told Endpoints News. Radhakrishnan...
View ArticleClik here to view.
Ultimovacs’ cancer vaccine UV1 flunks Phase 2 head and neck cancer trial
For a second time this year, Ultimovacs saw its stock crash after reporting its cancer vaccine failed in a Phase 2 study in head and neck squamous cell carcinoma. Topline data from the Phase 2 FOCUS...
View ArticleBayer details 3,200 job cuts so far, spotlights ‘momentum’ in pharma pipeline
Bayer is “on track” to realize the €2 billion in cost savings it’s aiming for in 2026, executives say, even as they report another quarter of “modest” performance across its crop science,...
View Article